Ability of Bicarbonate Supplementation To Sensitize Selected Methicillin-Resistant Staphylococcus aureus Strains to β-Lactam Antibiotics in an Ex Vivo Simulated Endocardial Vegetation Model

Warren E. Rose, Ana M. Bienvenida, Yan Q. Xiong, Henry F. Chambers, Arnold S. Bayer, Selvi C. Ersoy

ABSTRACT

Supplementation of standard growth media (cation-adjusted Mueller-Hinton Broth [CAMHB]) with bicarbonate (NaHCO₃) increases β-lactam susceptibility of selected methicillin-resistant Staphylococcus aureus (MRSA) strains (“NaHCO₃ responsive”). This “sensitization” phenomenon translated to enhanced β-lactam efficacy in a rabbit model of endocarditis. The present study evaluated NaHCO₃-mediated β-lactam MRSA sensitization using an ex vivo pharmacodynamic model, featuring simulated endocardial vegetations (SEVs), to more closely mimic the host microenvironment. Four previously described MRSA strains were used: two each exhibiting in vitro NaHCO₃-responsive or NaHCO₃-nonresponsive phenotypes. Cefazolin (CFZ) and oxacillin (OXA) were evaluated in CAMHB with or without NaHCO₃. Intra-SEV MRSA killing was determined over 72-h exposures. In both “responsive” strains, supplementation with 25 mM or 44 mM NaHCO₃ significantly reduced β-lactam MICs to below the OXA susceptibility breakpoint (≤4 mg/liter) and resulted in bactericidal activity (≥3-log killing) in the model for both OXA and CFZ. In contrast, neither in vitro-defined nonresponsive MRSA strain showed significant sensitization in the SEV model to either β-lactam. At both NaHCO₃ concentrations, the fractional time above MIC was >50% for both CFZ and OXA in the responsive MRSA strains. Also, in media containing RPMI plus 10% Luria-Bertani broth (proposed as a more host-mimicking microenvironment and containing 25 mM NaHCO₃), both CFZ and OXA exhibited enhanced bactericidal activity against NaHCO₃-responsive strains in the SEV model. Neither CFZ nor OXA exposures selected for emergence of high-level β-lactam-resistant mutants within SEVs. Thus, in this ex vivo model of endocarditis, in the presence of NaHCO₃ supplementation, both CFZ and OXA are highly active against MRSA strains that demonstrate similar enhanced susceptibility in NaHCO₃-supplemented media in vitro.

KEYWORDS MRSA, bicarbonate, Staphylococcus aureus, beta-lactams, bicarbonate, methicillin resistance

Methicillin-resistant Staphylococcus aureus (MRSA) is an important human pathogen that is associated with both community-onset and nosocomial-onset infections. Despite development of newer anti-MRSA antibiotics over the past decades (e.g., daptomycin, linezolid, oritavancin, dalbavancin, and ceftaroline) (1, 2), therapeutic issues with these agents, such as emergence of resistance or toxicities, have
often limited their utility (3–5). In turn, clinicians continue to rely on older anti-MRSA agents with proven efficacy (vancomycin), often employing multidrug combination treatments (6).

One of the limitations of antibiotic use is the predictive value of antimicrobial susceptibility testing and breakpoint determinations for selection. Although other diagnostics for infectious diseases have rapidly evolved over the past decades, antimicrobial susceptibility testing for MRSA has largely remained unchanged since the 1960s, with the use of bacterial growth medium such as Mueller-Hinton broth and agar (MHB and MHA). For *S. aureus* susceptibility testing with oxacillin (OXA), the Clinical and Laboratory Standards Institute (CLSI) recommends growth of bacteria in 2% NaCl cation-adjusted MHB (CAMHB) (7, 8). Although the latter medium will amplify the capacity to isolate OXA-resistant subpopulations within MRSA strains, it does not accurately reflect the host milieu; thus, the resulting MICs may not accurately represent antibiotic activity against MRSA within host-specific microenvironments (9).

Recent studies have focused on refining *in vitro* growth media to better simulate the host microenvironment in vivo in the context of more relevant and translatable antimicrobial susceptibility testing. Supplementation of standard media with bicarbonate (NaHCO₃), a ubiquitous buffer in humans (normally in the range of 23 to 29 mmol/liter in vivo), has become the subject of several such studies (9, 10). These reports have demonstrated the ability of NaHCO₃ supplementation to augment the susceptibility of selected MRSA strains *in vitro* to β-lactams. These investigations have focused on two conventional, prototype β-lactams not recommended for use against MRSA: OXA and cefazolin (CFZ) (10). These data enabled identification of two distinct MRSA phenotypes, “NaHCO₃ responsive” and “NaHCO₃ nonresponsive.” These *in vitro* phenotypes accurately predicted the ability of these same β-lactams to clear MRSA from multiple target tissues in a rabbit model of MRSA infective endocarditis (i.e., cardiac vegetations, kidneys, and spleen) (10). The mechanism(s) by which NaHCO₃ sensitizes “responsive” strains to such β-lactams appear to involve, at least in part, multiple genes which are critical in maintaining the MRSA phenotype, such as *mecA* and *sarA* (8); these perturbations may, in turn, lead to decreased production and/or maturation of PBP2a, yielding a “functional MSSA” phenotype (10).

The present study expands on our previous findings of bicarbonate sensitization of MRSA to β-lactams using a pharmacodynamic model featuring *ex vivo* simulated endocardial vegetations (SEVs). We hypothesized that “bicarbonate responsiveness” in MRSA in this model would mirror similar findings in the rabbit endocarditis model and that host-mimicking media within SEVs would help identify novel pharmacodynamic optimization strategies for prototypical β-lactams against such NaHCO₃-responsive MRSA strains.

**RESULTS**

**β-Lactam susceptibilities in standard and alternative media supplemented with NaHCO₃.** CFZ and OXA MICs have been previously reported for these four study strains (10). In this investigation, we confirmed the strain-dependent NaHCO₃ enhancement of the susceptibility of these isolates to the two study β-lactams. As noted in Table 1, strains 11-11 (USA300; ST8 and SCCmec IV) and MW2 (USA400; ST1 and SCCmec
IV) displayed a significant reduction in β-lactam MICs in media supplemented with NaHCO₃ (44 mM), while β-lactam susceptibility was not affected with NaHCO₃ supplementation for the other two strains, COL (USA100; ST250 and SCC mec I) and BMC-1001 (USA500; ST8 and SCC mec IV). In the two NaHCO₃-responsive strains, supplementation with 44 mM NaHCO₃ reduced the CFZ MIC to below the OXA susceptibility breakpoint (≤4 mg/liter), with an 8- to 16-fold MIC reduction. Similarly, for these same strains, the OXA MICs were reduced 16- to 64-fold with 44 mM NaHCO₃ supplementation.

It has recently been reported that an “antibiotic sensitization” effect, especially for Gram-negative bacteria and selected β-lactams, can occur in other host-mimicking media (9–11). The standard cell culture medium, RPMI 1640, contains physiologic concentrations of NaHCO₃ (~25 mM). In this medium, as opposed to CAMHB, we noted substantially increased β-lactam susceptibility in all four strains regardless of genotypic background. However, the two NaHCO₃-responsive strains were generally more responsive in this host-mimicking media, with resultant β-lactam MICs of ≤2 mg/liter (Table 1), which is consistent with previous findings (10).

β-Lactam pharmacokinetics in the ex vivo SEV model. The pharmacokinetic profiles of antibiotics within the ex vivo SEV model is computer designed to precisely mimic actual patient exposures clinically. Table 2 provides the predicted versus observed pharmacokinetic profiles of CFZ and OXA in the SEV model’s central “fluid” compartment (media; see Fig. 4). We simulated high-dose CFZ administration (2 g every 8 h) and OXA (2 g every 6 h), as recommended for invasive MSSA infections (12, 13). Also, these dose regimens approximate those used in our prior rabbit endocarditis study with these same strains (14). The concentrations achieved in the ex vivo model closely correlated to the targeted parameters for both antibiotics.

Antimicrobial activity in the ex vivo SEV model. For the antibiotic activities in the ex vivo SEV pharmacodynamic model, see Fig. 1 and 3. Table 3 compares the ability of each β-lactam to reduce the MRSA counts within the SEVs over the 72-h course of treatment (expressed as the area under the bacterial curves [AUBC]). As a point of reference,

### Table 2 Pharmacokinetics of CFZ and OXA in the central compartment (medium) of the pharmacodynamic model

| Parameter | CFZ, 2 g every 8 h | OXA, 2 g every 6 h |
|-----------|-------------------|-------------------|
|           | Predicted | Observed (n = 12) | Predicted | Observed (n = 12) |
| C<sub>max</sub> (mg/liter) | 256 | 249.4 ± 2.7 | 150 | 152.1 ± 1.4 |
| C<sub>min</sub> (mg/liter) | 16 | 15 ± 1 | 2.3 | 2.2 ± 0.1 |
| k<sub>o</sub> (h⁻¹) | 0.385 | 0.35 ± 0.032 | 0.693 | 0.705 ± 0.005 |
| Half-life (h) | 1.8 | 2.0 ± 0.2 | 1 | 1.0 ± 0.0⁶ |
| AUC<sub>0-24</sub> (mg/liter · h) | 2,442 | 2,384 ± 31 | 1,162 | 1,217 ± 91 |

*Data for observed values are presented as means ± the standard errors.

### Table 3 Area under the bacterial curve of CFZ and OXA treatment in standard and alternative media

| Regimen | Medium or media | Mean AUBC ± SD | 11-11 | MW2 | COL | BMC-1001 |
|---------|----------------|---------------|------|-----|-----|----------|
| CFZ     | CAMHB-Tris (control) | 626.2 ± 6.6  | 658 ± 3.0 | 648.4 ± 2.8 | 633.9 ± 4.5 |
|        | CAMHB-Tris + 25 mM NaHCO₃ | 455.3 ± 4.8⁶ | 489.2 ± 2.5⁶ | 612.1 ± 2.5 | 592.7 ± 3.4 |
|        | CAMHB-Tris + 44 mM NaHCO₃ | 310.0 ± 10.5⁶ | 290.8 ± 4.8⁶ | 601.9 ± 4.5 | 566.7 ± 2.9⁶ |
|        | RPMI 1640 + 10% LB medium | 378.3 ± 3.5⁶ | 387.3 ± 6.9⁶ | 505.3 ± 8.1⁶ | 538.8 ± 6.3⁶ |
| OXA    | CAMHB-Tris | 610 ± 3.5 | 661.9 ± 9.5 | 621.1 ± 3.6 | 642.4 ± 5.1 |
|        | CAMHB-Tris + 25 mM NaHCO₃ | 480 ± 6.3⁶ | 539.2 ± 23.3⁶ | 596.7 ± 6.7 | 617.3 ± 2.6 |
|        | CAMHB-Tris + 44 mM NaHCO₃ | 392 ± 17.8⁶ | 399.4 ± 15.0⁶ | 568.9 ± 11.0⁶ | 603.0 ± 538 |
|        | RPMI 1640 + 10% LB medium | 415.1 ± 4.2⁶ | 438.1 ± 9.3⁶ | 649.7 ± 4.7 | 599.1 ± 9.4 |

*The area under the bacterial curve (AUBC) is inversely related to antibiotic activity, with lower AUBC indicating greater antibiotic effect. The data represent means ± the standard deviations of duplicate replicates, with two samples taken at each time point (n = 4). CAMHB-Tris includes 2% NaCl.

⁶P < 0.05 versus control.

⁶P < 0.05 versus 25 mM NaHCO₃.
the less the AUBC, the more active the antibiotic regimen (14). The following trends emerged from these studies:

(i) The β-lactams were inactive against all MRSA in the ex vivo SEV model with CAMHB in the central compartment without bicarbonate supplementation. As expected, based on the intrinsic MICs, neither CFZ nor OXA had a substantive microbiologic effect against the four strains in the SEV model at human-equivalent, pharmacokinetic-based simulated dose-regimens. The activity curves among the strains were indistinguishable regardless of clonal background at all time points (Fig. 1 and 2), as well as for the overall exposure based on similar AUBC values (Table 3). Based on the MICs determined in CAMHB, OXA achieved zero percent ft>MIC (time above MIC of the free drug) for all strains, while CFZ achieved zero percent ft>MIC for COL and BMC-1001 and 33 and 57% ft>MIC for 11-11 and MW2, respectively.

(ii) Bicarbonate supplementation of CAMHB in the central compartment resulted in significant CFZ or OXA bactericidal activity in responsive (but not in nonresponsive) MRSA strains in the ex vivo SEV model. Figure 1 displays the pharmacodynamic SEV kill curve of CFZ against all four strains, with or without NaHCO3 supplementation. Based on MIC reductions noted in strains 11-11 and MW2 in this study, as well as in our previous in vitro work (14), we predicted that CFZ and OXA would each yield substantial intra-SEV antimicrobial activity against these responsive strains in the presence of NaHCO3 supplementation. Accordingly, in the ex vivo SEV model supplemented with NaHCO3, CFZ and OXA resulted in significantly greater anti-MRSA activity compared to standard CAMHB medium in these responsive strains. After 8 h in the SEV model, β-lactam exposures in bicarbonate-supplemented media resulted in significantly greater activity compared to standard CAMHB media (Fig. 1, P < 0.05 for time points 8 to 72 h). In comparing ex vivo kill curves between the different NaHCO3 concentrations, β-lactam exposure of the “responsive strains” in CAMHB medium supplemented with 44 mM NaHCO3 yielded a significantly greater bacterial count reduction for both CFZ and OXA versus 25 mM NaHCO3 supplementation at most time points from 24 to 72 h (Fig. 1 and 2, P < 0.05). In contrast, there was no difference in killing of the nonresponsive strains, COL and BMC-1001, with NaHCO3 supplementation (versus either antibiotic-containing standard CAMHB medium or in untreated growth controls) (P > 0.05).

Overall, there was a notable NaHCO3 concentration response, with higher bacterial count reductions, faster time to bactericidal activity (i.e., the time to a ≥3 Log10 CFU/g reduction), and lower AUBC when media were supplemented with 44 mM versus 25 mM NaHCO3 (Fig. 1 and Table 3). This correlated with greater susceptibility with the higher NaHCO3 concentration, resulting in 100% ft>MIC for both strains 11-11 and MW2 with 44 mM NaHCO3 versus 57 and 83% ft>MIC, respectively, with 25 mM NaHCO3 for these strains. Since no change in MIC occurred in CAMHB plus NaHCO3 in the nonresponsive strains, the ft>MIC remained at zero percent, and this reflects the lack of any β-lactam activity against those strains.

CFZ and OXA are each bactericidal ex vivo against NaHCO3 responsive (but not against nonresponsive) MRSA in the host-mimicking medium, RPMI. As noted above, the CFZ and OXA MICs for all four strains were substantially reduced in RPMI. We next determined whether these in vitro outcomes were mirrored ex vivo in the SEV model. As displayed in Fig. 3, the NaHCO3-responsive strains 11-11 and MW2 were significantly killed with CFZ or OXA treatment in this medium; this is reflected by the enhanced pharmacodynamic attainment in this medium, resulting in 100% ft>MIC for CFZ and 60% ft>MIC for OXA against both 11-11 and MW2 strains. In contrast, over the same 72-h β-lactam exposure period, the two nonresponsive strains (COL and BMC-1001) were minimally affected by either agent. It should be noted that there was initial activity with CFZ against COL in RPMI, with ~2 Log10 CFU/g killing at 24 to 48 h. However, this was not sustained after 48 h, and the strain regrew to the initial inoculum. These data are reflected in the lower target attainment of 8.2 to 56% ft>MIC for CFZ and 0 to 20% for ft>MIC for OXA.
β-Lactam treatment did not select for high-level CFZ or OXA resistance regardless of the NaHCO₃ responsivity phenotype. One additional advantage of this ex vivo model system is the ability to screen for emergence of drug-resistant mutants during human-simulated treatment strategies. In all our SEV simulations, we screened for evolution of high-level β-lactam-resistant mutants (≥4× the initial MIC) at time zero versus every

![Graphs showing kill curve activity of simulations for CFZ administered at 2 g every 8 h in the ex vivo SEV model.](image)

**FIG 1** Kill curve activity of simulations for CFZ administered at 2 g every 8 h in the ex vivo SEV model in standard media and in NaHCO₃-supplemented media against MRSA strains 11-11 (A), MW2 (B), COL (C), and BMC-1001 (D). The dashed line indicates untreated growth in CAMHB-Tris, and the solid lines indicate CFZ regimens. *, P < 0.05 versus CAMHB; **, P < 0.05 versus CAMHB plus 25 mM NaHCO₃ media.
24 h thereafter. No such resistant variants were confirmed over the course of treatment with either CFZ or OXA.

**DISCUSSION**

The $\beta$-lactam class of antibiotics remains the treatment of choice for a broad range of susceptible pathogens due to their potent and rapid mechanism(s) of action, as well
as their relatively low rates of adverse side effects and toxicities. In addition, they have recently become well characterized as able to augment the innate host immune system via their synergistic interactions with host defense peptides against key Gram-positive pathogens, including *S. aureus* (15–17).

The present study extends our previous work on the ability of NaHCO₃ supplement-

---

**FIG 3** Kill curve activity of simulations for CFZ administered at 2 g every 8 h and OXA administered at 2 g every 6 h in an ex vivo SEV model in host-mimicking RPMI–10% LB media against MRSA strains 11-11 (A), MW2 (B), COL (C), and BMC-1001 (D). *P < 0.05 versus control.
tation of standard MRSA *in vitro* media to identify a subset of MRSA strains that may, in fact, exhibit β-lactam susceptibility (10, 18, 19). The notion of using alternative media for antibiotic susceptibility screening is not new; however, the biological basis and clinical utility of this approach has substantially increased in the last few years in a variety of bacteria, including *Salmonella*, *Acinetobacter*, and *Staphylococcus* spp. (9, 11, 19). It should be emphasized that all four of our prototype MRSA isolates were rendered significantly more β-lactam susceptible *in vitro* in RPMI media (4- to 64-fold MIC reductions). However, these salutary *in vitro* results in RPMI did not accurately predict subsequent microbiologic outcomes in the SEV model.

The enhanced antimicrobial activity seen above in such alternative media, as well as their outcome predictability *in vivo*, may, in part, reflect (i) the enhanced activity of host defense peptides in combination with antibiotics *in vivo*, (ii) bacterial adaptations *in vivo* that prevent excessive microbial growth, and/or (iii) blunted expression of antimicrobial resistance mechanisms (10, 11, 16). However, it should be noted that some host-mimicking environments may actually be beneficial for bacterial survival. For example, under more acidic conditions, *Escherichia coli* may become more resistant to β-lactams due to the higher PBP1b production needed for organism survival in this harsh environment (20).

The treatment of MRSA infections poses several daunting challenges. Current treatment options for MRSA infections are relatively limited and include antibiotics that are not only costly but also substantially less effective and often more toxic compared to standard antibiotic treatments for MSSA (21–23). This is in large part due to the perceived inability to use traditional β-lactam antibiotics for MRSA infections (2). The *mecA* gene is primarily responsible for mediating *S. aureus* resistance to traditional β-lactams, encoding penicillin-binding protein 2A (PBP2A), which has low affinity to most standard-of-care antistaphylococcal β-lactam antibiotics (2). Despite this, combination therapy featuring β-lactams plus anti-MRSA agents such as vancomycin and daptomycin has proven to be effective in selected patients with recalcitrant MRSA infections (15, 24–27). In addition, many MRSA strains that exhibit reduced susceptibility to vancomycin and daptomycin often demonstrate a paradoxical increase in susceptibility to β-lactams, a phenomenon known as the “see-saw effect”; this provides an additional scenario in which β-lactam agents may provide synergistic efficacy for MRSA killing (15).

Following our discovery of the NaHCO3-responsive phenotype in several prototype MRSA strains in terms of β-lactam hypersusceptibility *in vitro* (10), we recently screened a large collection of well-characterized MRSA strains (*n* = 58) for this same phenotype. We identified that approximately three-quarters of this cohort were CFZ susceptible in NaHCO3-supplemented CAMHB, whereas approximately one-third were OXA susceptible in the same media (28). The more active effect of CFZ in our *ex vivo* SEV model, as well as in the rabbit endocarditis model (10), would support this finding.

We investigated the potential mechanisms by which NaHCO3 may cause such β-lactam hypersusceptibility *in vitro* and demonstrated that NaHCO3-supplemented media can (i) downregulate expression of the *mecA* gene and subsequent PBP2a production and (ii) blunt the expression of several genes involved in maintenance of the MRSA phenotype, including *sarA* and *blaZ* (10). In MRSA, PBP4 is also essential for peptidoglycan cross-linking (29), so it will be of interest to determine whether NaHCO3 responsiveness in selected MRSA strains might result from the downregulation of PBP4 expression and reduction in that protein’s production. This additional potential mechanism is under investigation.

The pharmacodynamic parameter best correlated with efficacy of β-lactam antibiotics is *fT>MIC*; this metric has been highly studied *in vivo* and *in vitro* and has been validated to predict improved clinical outcomes in β-lactam-treated patients (30–33). In most investigations, β-lactams demonstrate optimal activity with a “target attainment” of *fT>MIC* in the range of 40 to 60% (30). Relevant to our study, we found that the lower MICs observed in NaHCO3-supplemented media for two of our prototype strains—11-11 and MW2—resulted in an “MSSA-like phenotype,” improving the po-
tential for target attainment for both CFZ and OXA. For the NaHCO₃-responsive strains, CFZ achieved at least 83% $T_{\text{MIC}}$, resulting in a substantial and durable bactericidal activity in the ex vivo SEV model. Similarly, OXA, with a calculated $\sim$60% $T_{\text{MIC}}$ in the two NaHCO₃-responsive strains, also achieved good bactericidal activity in the ex vivo model. The effect of higher doses of oxacillin as recommended for humans with endocarditis ($\geq$12 g/day), as well as alternative infusion strategies (such as continuous infusion) are being explored to optimize this NaHCO₃-responsive phenotype in our SEV model.

The ex vivo SEV model has been extensively used to pharmacokinetically and pharmacodynamically study the impacts of many antimicrobials against a number of clinical bacterial isolates; these investigations have focused on verifying these organism-antimicrobial interactions in a setting more akin to the host tissue microenvironment than standard in vitro assays (34, 35). In addition, this model has been shown to successfully recapitulate the microbiologic results generated in several in vivo animal models, including rabbit endocarditis (36). In the present investigation, we used this same ex vivo pharmacokinetic/pharmacodynamic model to more systematically evaluate the activity of CFZ and OXA against our four prototype MRSA isolates in a host-mimicking microenvironment. Our current results in the SEV model further strengthen an important “bridge” between in vitro and in vivo outcomes with these strains. First, the two MRSA strains that were significantly $\beta$-lactam/NaHCO₃ responsive in vitro and in vivo (10) showed enhanced intra-SEV killing by CFZ and OXA in the presence of NaHCO₃. In parallel, the two $\beta$-lactam/NaHCO₃-nonresponsive strains (as defined in vitro and in vivo) were not substantially killed by CFZ or OXA ex vivo. Second, as seen in vitro, there appeared to be a NaHCO₃ concentration optimum for the $\beta$-lactam/NaHCO₃-sensitizing phenotype for the two responsive strains (11-11 and MW2). Thus, significant killing was seen ex vivo within SEVs both at 25 and 44 mM, but with a substantially greater bactericidal effect seen at the latter concentration. In contrast, the excellent in vivo clearance of both NaHCO₃-responsive MRSA which occurs in vivo at NaHCO₃ concentrations of 20 to 25 mM (10) suggests that additional host factors within cardiac vegetations or other target organs are in play to synergistically kill MRSA (e.g., higher tissue levels of NaHCO₃ than blood levels or additive antimicrobial actions of polymorphonuclear leukocytes, platelets, host defense peptides, and/or antibody, etc. [9–11]).

In conclusion, this study further validates the potential clinical transatability of the intriguing finding of $\beta$-lactam/NaHCO₃ sensitization of selected MRSA strains in vitro. It will be important to extend our studies to even larger clinical MRSA cohorts (28). Ultimately, a pivotal human trial will be required to fully adjudicate the clinical utility of defining MRSA strains as $\beta$-lactam/NaHCO₃ responsive in the clinical microbiology laboratory. There may be supportive data to justify this in the literature, e.g., the equivalent efficacy of the $\beta$-lactam, cephaloxin, versus clindamycin in a randomized controlled clinical trial for MRSA skin infections (37) (despite cephaloxin resistance by traditional in vitro susceptibility testing). These prior studies provide support for an ultimate clinical trial to assess the notion of $\beta$-lactam/NaHCO₃ responsiveness in MRSA.

**MATERIALS AND METHODS**

**Bacterial strains, media, and antibiotics.** The strains used in this study were all clinical MRSA isolates and represent diverse contemporary clonal genotypes (USA types) found worldwide in MRSA infections. These included MRSA 11-11 (USA300), MW2 (USA400), COL (USA100), and BMC-1001 (USA500). These strains are well described in the literature and were recently utilized to define NaHCO₃ response in vitro (10). All strains were stored at −80°C in tryptic soy broth with 15% glycerol until thawed for use. Bacteria were cultured on MHA and incubated at 37°C in ambient air. Liquid culture medium used for bacterial growth in susceptibility testing, and pharmacodynamic modeling included four different types: (i) cation-adjusted Mueller-Hinton broth (CAMHB; Difco) with the addition of 100 mM Tris (hydroxymethyl-aminomethane; Fisher Scientific) to maintain pH at approximately 7.3 ± 0.1, (ii) CAMHB-Tris supplemented with 25 mM NaHCO₃ (iii) CAMHB-Tris supplemented with 44 mM NaHCO₃, or (iv) tissue culture medium, Roswell Park Memorial Institute (RPMI) 1640 (Fisher Scientific) supplemented with 10% Luria-Bertani (LB) broth. The latter medium contains ~25 mM NaHCO₃, as well as biotin, vitamin B₁₂, and PABA, as well as vitamins, inositol, and choline. Also, all four liquid medium types were supplemented with 2% NaCl as recommended by the CLSI. The $\beta$-lactam antibiotics OXA and CFZ were...
purchased as analytical powders from Sigma-Aldrich (St. Louis, MO) and prepared fresh prior to each experiment according to the manufacturer’s protocols.

**Antibiotic susceptibility assays.** CLSI guidelines (7) for broth microdilution were used to determine antibiotic susceptibilities (MICs) with modifications to the recommended media (8). Bacteria were grown overnight at 35°C on MHA, and resulting colonies were suspended in the different media listed above to the equivalent of 0.5 McFarland standard. Samples were further diluted 1:100 for a final inoculum of $5 \times 10^5$ CFU/ml. Antibiotics were serially diluted 2-fold, and MICs were defined by standard metrics (7) and determined in triplicate on two separate days ($n = 6$ replicates).

**Pharmacodynamic model with ex vivo SEVs.** The SEV model components and characteristics are illustrated in Fig. 4. Pooled human cryoprecipitate antihemophilic factor prepared from plasma (fibrinogen, von Willebrand factor, factor VIII, factor XIII, and fibronectin), and pooled platelets were collected from human volunteer donors (UW Health Blood Bank, Madison, WI). C Bovine thrombin (UW Health) and aprotinin (Sigma-Aldrich) were commercially purchased. This preparation results in SEVs containing 3 to 3.5 g/dl of albumin and 6.8 to 7.4 g/dl of total protein (equating to human physiologic levels) (17, 34). The protein binding of the study drugs has been found to be 84% for CFZ and 92% for OXA, which was used to calculate the free AUC ($\int_{0}^{T} fAUC$) and the percent time of free drug above the MIC (%$fT/MIC$) (38, 39).

The central (“fluid”) compartment model for the SEVs consists of a 150-ml flask, which was prefilled with media and magnetic stir bar, and SEVs were added for 30 min prior to antibiotic dosing to allow for climate acclimation. The model was maintained at 35 to 37°C ambient air and fresh medium instilled via a continuous syringe pump system (New Era Pump Systems, Inc.) to provide a human pharmacokinetic simulation of the antibiotics. All model experiments were performed in duplicate flasks to ensure reproducibility with two SEVs collected for each time point ($n = 4$ SEVs per time point). After collection from the model, SEVs were weighed and placed in sterile 1.5-ml microcentrifuge tubes containing 1.0-mm sterile glass beads, and 500 μl of trypsin (from a 25-mg/ml stock) was added (Fig. 4). Tubes were vortexed at medium speed for 1 h, and digested SEVs were plated on MHA plates using a WASP 2 spiral plater (Microbiology International, Frederick, MD). Bacteria were quantified by using a Scan 300 colony counter (Interscience, Woburn, MA), and data are reported as CFU/g of SEV tissue.

**Simulated antimicrobial regimens.** All regimens were derived from human pharmacokinetic data and standard dosing regimens for humans with MSSA infections previously published and to mimic previous exposures in the rabbit endocarditis model (14) as follows: OXA, 2 g infused every 6 h (10); or CFZ, 2 g infused every 8 h (40, 41). Antibiotics were administered as boluses over 1 min into a Luer lock port of the flask (Fig. 4) at the scheduled administration time over a 72-h dosing duration. The predicted pharmacokinetics of each regimen are provided in Table 2.

**Pharmacokinetic analysis and exposure determination.** Pharmacokinetic samples were obtained in duplicate through the injection port of each model from 0 to 72 h for verification of target antibiotic concentration attainment. All samples were stored at ~80°C until ready for analysis. Concentrations of
OXA were determined by bioassay using *Kocuria rhizophila* ATCC 9341 on MHA as previously described [41]. The concentrations of CFZ were determined by bioassay using the temperate *Bacillus subtilis* ATCC 6633 on MHA (42). The half-lives, areas-under-the-curve 0 to 24 h (AUC), and maximum and minimum concentrations (C_{max} and C_{min}) of each antibiotic were determined by the trapezoidal method utilizing Prism (GraphPad Software, Inc.). The observed /AUIC/MMC and %FT>MIC values were determined in Prism and reported for OXA and CFZ.

Assessment for emergence of variants with high-level β-lactam resistance in the ex vivo model. Samples (100 μl) from each time point were parallel plated onto MHA plates containing either no antibiotic or 4-fold the respective β-lactam initial MICs to assess for the emergence of high-level-resistance mutants. The plates were then examined for growth after 48 h of incubation at 35°C. Specific CFZ or OXA MICs were then determined on selected colonies exhibiting growth on the respective antibiotic-containing agar plates to quantify the actual changes in MIC over the 72-h β-lactam exposure period of 19.

Statistical analysis. Bacterial counts, expressed as the log_{10} CFU/g, in SEVs at each time point were determined for each antibiotic treatment and growth condition for each strain. The AUBC, defined as area under the bacterial growth curves over the 72-h experiments, was also calculated. A two-way analysis of variance was used with a Tukey’s test to compare bacterial counts and an AUBC with a *P* value of ≤ 0.05 for significance. All statistical comparisons were analyzed using Prism 8 (GraphPad Software, San Diego, CA).

ACKNOWLEDGMENTS

This study was supported in part by research grants from the National Institutes of Health to A.S.B. (NIADDQ1AII146078-01) and W.E.R. (NIADDQ1AII132627-02).

We thank Sally Griffith-Oh for creating the figure for illustration.

REFERENCES

1. Lee AS, de Lencastre H, Garau J, Kluymans L, Malhotra-Kumar S, Peshel A, Harbarth S. 2018. Methicillin-resistant *Staphylococcus aureus*. Nat Rev Dis Primers 4:18033. https://doi.org/10.1038/s41575-018-0033.

2. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, Carugati M, Holland TL, Fowler VG, Jr. 2019. Methicillin-resistant *Staphylococcus aureus*: an overview of basic and clinical research. Nat Rev Microbiol 17:203–218. https://doi.org/10.1038/s41579-018-0147-4.

3. Bayer AS, Mishra NN, Chen L, Kiesewirth BN, Rubio A, Yang SJ. 2015. Frequency and distribution of single-nucleotide polymorphisms withinmprF in methicillin-resistant *Staphylococcus aureus* clinical isolates and their role in cross-resistance to daptomycin and host defense antimicrobial peptides. Antimicrob Agents Chemother 59:4930–4937. https://doi.org/10.1128/AAC.00970-15.

4. Lee H, Yoon E-J, Kim D, Kim JW, Lee K-J, Kim HS, Kim YR, Shin JH, Shin JH, Shin KS, Kim YA, Uh Y, Jeong SH, Lee H, Yoon E-J, Kim D, Kim JW, Lee K-J, Kim HS, Kim YR, Shin JH, Shin JH, Shin KS, Kim YA, Uh Y, Jeong SH. 2018. Cefartoline resistance by clone-specific polymorphism in penicillin-binding protein 2a of methicillin-resistant *Staphylococcus aureus*. Antimicrob Agents Chemother 62:e0485-18. https://doi.org/10.1128/AAC.00485-18.

5. Kullar R, Sakoulas G, Deresinski S, van Hal SJ. 2016. When sepsis persists: a review of MRSA bacteraemia salvage therapy. J Antimicrob Chemother 71:576–586. https://doi.org/10.1093/jac/dkv368.

6. Projan SJ, Shaels DM. 2004. Antibacterial drug discovery: is it all downhill from here? Clin Microbiol Infect 10(Suppl 4):18–22. https://doi.org/10.1111/j.1465-0969.2004.1006.x.

7. Clinical and Laboratory Standards Institute. 2015. Methods for antimicrobial dilution susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.

8. Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing. CLSI document M100-ED29. Clinical and Laboratory Standards Institute, Wayne, PA.

9. Ersoy SC, Heithoff DM, Barnes L, Tripp GK, House JK, Marshall JW, Mahan MJ. 2017. Correcting a fundamental flaw in the paradigm for antimicrobial susceptibility testing. EbioMedicine 20:173–181. https://doi.org/10.1016/j.ebiom.2017.05.026.

10. Ersoy SC, Abdelhady W, Li L, Chambers HF, Xiong YQ, Bayer AS, Ersoy SC, Abdelhady W, Li L, Chambers HF, Xiong YQ, Bayer AS. 2019. Bicarbonate resensitization of methicillin-resistant *Staphylococcus aureus* to beta-lactam antibiotics. Antimicrob Agents Chemother 63:e00496-19. https://doi.org/10.1128/AAC.00496-19.

11. Lin L, Nonejue P, Munguija J, Hollands A, Olson J, Dam Q, Kumaraswamy M, Rivera H, Jr, Corriden R, Rohde M, Hensler ME, Burkart MD, Pogliano J, Sakoulas G, Nizet V. 2015. Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant gram-negative bacterial pathogens. EbioMedicine 2:690–698. https://doi.org/10.1016/j.ebiom.2015.05.021.

12. Biddell MR, Patel N, O’Donnell JN. 2018. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. J Antimicrob Chemother 73:2643–2651. https://doi.org/10.1093/jac/dky259.

13. Tong SYC, Nelson J, Paterson DL, Fowler VG, Howden BP, Cheng AC, Chatfield M, Lipman J, Van Hal S, O’Sullivan M, Robinson JO, Yahav D, Lye D, Davis JS, CAMERA2 Study Group and the Australasian Society for Infectious Diseases Clinical Research Network. 2016. CAMERA2: combination antibiotic therapy for methicillin-resistant *Staphylococcus aureus* infection: study protocol for a randomised controlled trial. Trials 17:170. https://doi.org/10.1186/s13063-016-1295-3.

14. Volk CF, Burgdorf S, Edwardsong N, Nizet V, Sakoulas G, Rose WE. 2019. IL-1β and IL-10 host responses in patients with *Staphylococcus aureus* bacteraemia determined by antimicrobial therapy. Clin Infect Dis https://doi.org/10.1093/cid/ciz666.

15. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Sakoulas G. 2011. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteria due to methicillin-resistant *Staphylococcus aureus*: role of enhanced daptomycin binding. Clin Infect Dis 53:158–163. https://doi.org/10.1093/cid/cir340.

16. Sakoulas G, Okumura CY, Thienphrapa W, Olson J, Nonejue P, Dam Q, Dhand A, Pogliano J, Yeaman MR, Hensler ME, Bayer AS, Nizet V. 2014. Naftillin enhances innate immune-mediated killing of methicillin-resistant *Staphylococcus aureus*. J Mol Med 92:139–149. https://doi.org/10.1007/s00109-013-1100-7.

17. Rose WE, Leonard SN, Rybak MJ. 2008. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against *Staphylococcus aureus* isolates with reduced susceptibilities to daptomycin in an in vivo pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 52:3061–3067. https://doi.org/10.1128/AAC.00102-08.

18. Ribeiro LS, Migliari Branco L, Franklin BS. 2019. Regulation of innate immune responses by platelets. Front Immunol 10:1320. https://doi.org/10.3389/fimmu.2019.01320.

19. Kubicek-Sutherland JZ, Heithoff DM, Ersoy SC, Shimp WR, House JK, Marth JD, Smith JW, Mahan MJ. 2015. Host-dependent induction of transient antibiotic resistance: a prelude to treatment failure. Ebio-Medicine 2:1169–1178. https://doi.org/10.1016/j.ebiom.2015.08.012.

20. Mueller EA, Egan AJ, Breukink E, Vollmer W, Levin PA, Mueller EA, Egan...
AJ, Breukink E, Vollmer W, Levin PA. 2019. Plasticity of Escherichia coli cell wall metabolism promotes fitness and antibiotic resistance across environmental conditions. Elife 8:e05754. https://doi.org/10.7554/eLife.40754.

21. McDanel JS, Roghmann M-C, Perenich EV, Ohl ME, Goto M, Livorsi DJ, Jones M, Albertson JP, Nair R, O’Shea AMJ, Schweizer ML. 2017. Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study. Clin Infect Dis 65: 100–106. https://doi.org/10.1093/cid/ciz287.

22. Burrell CC, Broadbelt EK, Margulis A, Snyder GM, Gold HS, McCoy C, Mahoney MV, Hirsch 2018. Does the beta-lactam matter? Nafcillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bloodstream infections. Chemotherapy 63:345–351. https://doi.org/10.1159/000499033.

23. Pollett S, Baxi SM, Rutherford GW, Doernberg SB, Bacchetti P, Chambers HF. 2016. Cefazolin versus nafcillin for methicillin-sensitive Staphylococcus aureus bloodstream infection in a California tertiary medical center. Antimicrobial Agents Chemother 60:4684 –4689. https://doi.org/10.1128/AAC.00243-16.

24. Jorgensen SCJ, Zasowski EJ, Trinh TD, Lagnf AM, Bhatia S, Sabagha N, Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, Pogliano J, Johns S, Kaatz GW, Ebright JR, Nizet V. 2014. Antimicrobial pharmacokinetics and safety of high doses of ceforanide (bilobocillin) and ceftriaxone combinations against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 58:831–836. https://doi.org/10.1128/AAC.00869-17.

25. Casapao AM, Jacobs DM, Bowers DR, Beyda ND, Dilworth TJ, Group R-I. 2019. Early administration of admuvant beta-lactam therapy in combination with vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 60:4684–4689. https://doi.org/10.1128/AAC.00243-16.

26. Sakoulas G, Moise PA, Casapao AM, Nonejue P, Olson J, Okumura CY, Rybak MJ, Kullar R, Dhand A, Rose WE, Goff DA, Bressler AM, Lee Y, Pogliano J, Johns S, Kaatz GW, Ebrigt JR, Nizet V. 2014. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 36:1317–1333. https://doi.org/10.1016/j.clinthera.2014.05.061.

27. Davis JS, Sud A, O’Sullivan MVN, Robinson JO, Ferguson PE, Foo H, van Hal SJ, Ralph AP, Howden BP, Binks PM, Kirby A, Tong SYC, Tong S, Davis J, Binks P, Majumdar S, Ralph A, Baird R, Gordon C, Jeremiah C, Leung G, Brichtoet A, Crowe A, Dakk F, Whykes K, Kirkwood M, Sud A, Menon M, Somerville L, Subedi S, Owens S, O’Sullivan M, Liu E, Zhou F, Robinson O, Coombs G, Fusung P, Ralph A, Liu E, Pollett S, Van Hal S, Foo H, Van Hal SJ, Davis S. 2016. Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis 62:173–180. https://doi.org/10.1093/cid/civ088.

28. Esero SC, Zapata-Davila B, Otmishi M, Milan V, Li L, Chambers HF, Xiong YQ, Bayer AS. 2019. Scope and predictive genetic/phenotypic signatures of “bicarbonate-responsivity” and β-lactam sensitization among methicillin-resistant Staphylococcus aureus, absbr 607. IDWeek, Washington, DC.

29. Memmi G, Filipe SR, Pinho MG, Fu Z, Cheung A. 2008. Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrobial Agents Chemother 52:3955–3966. https://doi.org/10.1128/AAC.00049-08.

30. Lodise TP, Lomaestro BM, Drusano GL. Society of Infectious Diseases Pharmacists. 2006. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the society of infectious diseases pharmacists. Pharmacotherapy 26:1320–1332. https://doi.org/10.1592/phco.26.9.1320.

31. MacVane SH, Kuti JL, Nicolau DP. 2014. Prolonging beta-lactam infusion: a review of the rationale and evidence, and guidance for implementation. Int J Antimicrob Agents 43:105–113. https://doi.org/10.1016/j.ijantimicag.2013.10.021.

32. Andes D, Craig WA. 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 19: 261–268. https://doi.org/10.1016/S0924-8579(02)00022-5.

33. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1–10. https://doi.org/10.1086/516284.

34. Rose WE, Leonard SN, Sakoulas G, Kaatz GW, Zervos MJ, Sheth A, Carpenter CF, Rybak MJ. 2008. Daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 52:831–836. https://doi.org/10.1128/AAC.00869-17.

35. Rybak MJ, Allen GP, Hershberger E. 2001. In vitro antibiotic pharmacodynamic models, p 41–65. In Nightingale CH, Murakawa T, Ambrose PG (ed), Antimicrobial pharmacodynamics in theory and clinical practice. Marcel Dekker, Inc, New York, NY.

36. Kebriaei R, Rose SA, Stamper KC, Seepersaud R, Garcia-de-la-Maria C, Mishra NN, Miro JM, Arias CA, Tran TT, Sullam PM, Bayer AS, Rybak MJ. 2019. Daptomycin dose-ranging evaluation with single-dose versus multidose ceftriaxone combinations against Streptococcus mitis/oralis in an ex vivo simulated endocarditis vegetation model. Antimicrobial Agents Chemother 63:e00386-19. https://doi.org/10.1128/AAC.00386-19.

37. Chen AE, Carroll KC, Diener-West M, Ross T, Ordu J, Goldstein MA, Kulkarni G, Cantey JB, Siberry GK. 2011. Randomized controlled trial of cepalexin versus clindamycin for uncomplicated pediatric skin infections. Pediatrics 127:e573–e580. https://doi.org/10.1542/peds.2010-2053.

38. Standfast HC, Jordan MC, Kirby WM. 1970. Clinical pharmacology of carbenicillin compared with other penicillins. J Infect Dis 122(Suppl): S9–S13. https://doi.org/10.1093/infdis/122.supplement_1.9.

39. Smyth RD, Pfeffer M, Glick A, Van Harken DR, Hottendorf GH. 1979. In vitro antibiotic pharmacokinetics and safety of high doses of ceforanide (bls786r) and cefazolin. Antimicrob Agents Chemother 16:615–621. https://doi.org/10.1128/aac.16.5.615.

40. Hagiwara M, Wiskirchen DE, Kuti JL, Nicolau DP. 2012. In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 56:202–207. https://doi.org/10.1128/AAC.05473-11.

41. LaPlante KL, Rybak MJ. 2004. Impact of high-inoculum Staphylococcus aureus on the activities of vanillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrobial Agents Chemother 48:4665–4672. https://doi.org/10.1128/AAC.48.12.4665-4672.2004.

42. Fields MT, Herndon BL, Bamberger DM. 1993. Beta-lactamase-mediated inactivation and efficacy of cefazolin and cefmetazole in Staphylococcus aureus abscesses. Antimicrob Agents Chemother 37:203–206. https://doi.org/10.1128/aac.37.2.203.